In the cancer world — or anywhere — the ability to give thanks in the midst of trials is an acquired skill. It must be ...
A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback